. 2018 Apr 18;3(3):281–290. doi: 10.1177/2396987318771426

Table 2.

Participant schedule.

Activity	Run-in phase		Treatment phase
Activity	Day 0	Week 4	Week 0	Week 4	Week 13	Week 26	Week 52	Week 78	Week 104
Review eligibility	✓	✓
Informed consent	✓
Optimise preventative therapy	✓
Clinical evaluation^a	✓	✓		✓	✓	✓	✓		✓
Safety blood tests^b	✓	✓		✓	✓	✓	✓		✓
Blood for uric acid level		✓							✓
Blood/urine for biobanking		✓							✓
ECG		✓							✓
Echocardiography		✓
Determine cardiac sub-study eligibility		✓
MRI brain (± carotid MRI)		✓							✓
ABPM		✓		✓					✓
Cardiac MRI,^c n=100		✓							✓
Detailed cognitive function evaluation		✓							✓
Assessment of run in completion		✓
Randomisation			✓
Dispense			✓	✓	✓	✓	✓	✓
Return/count IMP				✓	✓	✓	✓	✓	✓
Adverse event review			✓	✓	✓	✓	✓	✓	✓

Note that the run in week 4 and treatment phase week 0 visits can take place concurrently. Participants will also be contacted by telephone at week 105, which marks the end of the study.

IMP: investigational medicinal product; ABPM: ambulatory blood pressure monitoring; ECG: electrocardiography; MRI: magnetic resonance imaging.

^aMeasures of stroke severity at week 4, modified Rankin scale score and MoCA at week 52 and blood pressure at all visits except week 78 and weight at week 104).

^bFBC, U + E, LFTs.

^cSub-study eligible participants only.